Inside Setidegrasib’s Phase 3 Development: Targeting KRAS G12D Through Protein Degradation / Astellas, docetaxel, KRAS G12D, KRAS G12D-Mutated NSCLC, Lung Inside Setidegrasib’s Phase 3 Development: Targeting KRAS G12D Through Protein Degradation Astellas announced that the first patient has been dosed...
Transcript: CancerNetwork: Given an OS hazard ratio of 0.18 and a median that was not reached in the KRAS G12C-mutated subgroup, what do you think is biologically distinct about G12C, specifically, vs other KRAS subtypes that could explain such an...
Posted on September 29, 2026 Astellas has dosed the first patient in a Phase III study evaluating setidegrasib in previously treated patients with KRAS G12D mutated advanced non small cell lung cancer. The study will compare the investigational treatment with...
Dr Herzberg on the Expanding Toolkit in KRAS-Mutant Non–Small Cell Lung Cancer Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks. In this episode of Targeted Talks, Benjamin...
This opening segment of a Biomarker Insights program recorded at the 2026 World Conference on Lung Cancer (WCLC) introduces the 2 biomarkers at its center, EGFR and KRAS G12C, in non-small cell lung cancer (NSCLC). The hosts outline a plan...
Astellas Pharma Inc. announced that the first patient has been dosed in a phase 3 study evaluating setidegrasib, a novel, investigational KRAS G12D-targeted protein degrader, versus docetaxel in people with KRAS G12D-mutated locally advanced (unresectable) or metastatic non-small cell lung...
Several next-generation KRAS G12C inhibitor plus checkpoint inhibitor combinations are already in clinical development. A retrospective analysis of the phase 3 EMPOWER-Lung 1 trial (NCT03088540), presented at the IASLC 2026 World Conference on Lung Cancer (WCLC), showed that patients with...
